Rethink “treatment-resistant depression” by adopting difficult-to-treat depression, verifying adequate trials, and stratifying drivers like trauma and inflammation to improve outcomes.
|Articles|May 15, 2019
- Psychiatric Times Vol 36, Issue 5
- Volume 36
- Issue 5
Conflict of Interest Form
Author(s)Richard M. Berlin, MD
They ask me to sign the moment before my poetry reading and I comply...
Advertisement
They ask me to sign
the moment before
my poetry reading
and I comply,
though I don’t let on
my conflicts are
my greatest interest-
how I profit from sickness,
the way I can be both
detached and concerned,
that my most inspired device
is to marry psychiatry’s science,
without conflict,
to the poetry of healing.
Articles in this issue
over 7 years ago
Introduction: Meeting Our Personal and Professional Goalsover 7 years ago
Locum Psychiatric Practice: Unexpected, Unheralded Benefitsover 7 years ago
The Role of Social Media in Private Practiceover 7 years ago
Disability: Overview of Concepts Psychiatrists Need to Knowover 7 years ago
Introduction to Immunotherapy of Malignancies for Psychiatristsover 7 years ago
Looking for AmericaAdvertisement
Related to this article
Once-monthly subcutaneous olanzapine LAI requires no loading doses, oral supplementation, or post-injection monitoring, based on phase 3 SOLARIS data.
Neurosterix advances NTX-253, an oral M4 PAM, into phase 2 for schizophrenia after phase 1 shows promising safety and pharmacokinetics.
Andrew A. Nierenberg, MD, explains how a learning health network helps clinicians measure outcomes and redesign bipolar disorder care together with patients.
Routine symptom measures sharpen psychiatric diagnosis, speed remission, flag relapse risk, and turn EHR data into a learning system for better care.
Seaport begins phase 2a trial of GlyphAgo for generalized anxiety disorder with sleep disturbance, testing liver-sparing agomelatine dosing and tracking sleep, anxiety outcomes.
FDA clears Motivista, a prescription smartphone digital therapeutic, to reduce negative symptoms of schizophrenia—supported by phase 3 results and strong patient engagement.
Vortioxetine eases depression in older adults, while cognitive gains stay mixed—showing selective boosts in attention and processing speed, not consistent global improvement.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Olanzapine LAI (Weltruza) Receives FDA Approval for Schizophrenia
2
Moving Away From Treatment-Resistant Depression and Toward Difficult-to-Treat Depression
3
Should Postpartum Psychosis Be Included in the DSM?
4
Blinding, Ethics, and Safety Safeguards in Psychedelic Clinical Research
5